Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | SCD | O00767 | 2/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.32 |
| ▸ | TUBB | P07437 | 1/20 | 0.32 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.32 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.32 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.32 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.32 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.32 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.32 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.32 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.32 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.32 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.32 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.32 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.32 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15846187 | 0.81 | KDM5B (0.36) | L3MBTL1 | |
| SCHEMBL6246780 | 0.81 | MPO (0.30) | — | |
| SCHEMBL6936934 | 0.80 | LMNA (0.40) | L3MBTL1SCDEGFRTUBB4ATUBB | |
| SCHEMBL671590 | 0.79 | — | — | |
| SCHEMBL17209860 | 0.79 | MEN1 (0.40) | L3MBTL1SCDEGFRTUBB4ATUBB | |
| SCHEMBL3007446 | 0.79 | ALDH1A1 (0.39) | L3MBTL1SCDEGFRTUBB4ATUBB | |
| SCHEMBL23012478 | 0.79 | L3MBTL1 (0.38) | L3MBTL1SCDEGFRTUBB4ATUBB | |
| SCHEMBL25839372 | 0.77 | L3MBTL1 (0.33) | L3MBTL1SCDEGFRTUBB4ATUBB | |
| SCHEMBL177537 | 0.76 | L3MBTL1 (0.41) | L3MBTL1 | |
| SCHEMBL13605810 | 0.75 | JAK2 (0.35) | L3MBTL1JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250340559-A1 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | INCYTE HOLDINGS CORP (US) | 2025-11-06 | — | — | US | disclosed |
| US-12247030-B2 | Process for preparing compositions comprising an enantiomeric excess of a substituted pyrrolo[2,3-d]pyrimidine | INCYTE HOLDINGS CORPORATION (US) | 2025-03-11 | — | — | US | disclosed |
| EP-4501410-A2 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | Incyte Holdings Corporation (US) | 2025-02-05 | — | — | EP | disclosed |
| CN-119306753-A | Methods for preparing JAK inhibitors and related intermediate compounds | 因西特控股公司 | 2025-01-14 | — | — | CN | disclosed |
| EP-3272738-B1 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | INCYTE HOLDINGS CORP (US) | 2024-11-13 | — | — | EP | disclosed |
| CN-108395433-B | Methods for preparing JAK inhibitors and related intermediate compounds | 因西特控股公司 | 2024-10-22 | — | — | CN | disclosed |
| US-20210253584-A1 | Processes for Preparing Jak Inhibitors and Related Intermediate Compounds | INCYTE HOLDINGS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| US-10975085-B2 | Process for preparing a composition comprising an enantiomeric excess of greater than or equal to 90% of the (R)-enantiomer of a compound of formula III | INCYTE HOLDINGS CORPORATION (US) | 2021-04-13 | — | — | US | disclosed |
| WO-2021032148-A1 | AMINOPYRAZINE COMPOUNDS AS HPK1 INHIBITOR AND THE USE THEREOF | BEIGENE, LTD. (KY) | 2021-02-25 | — | — | WO | disclosed |
| US-10364248-B2 | Processes for preparing 4-chloro-7H-pyrrolo[2,3-d]pyrimidine | INCYTE CORPORATION (US) | 2019-07-30 | — | — | US | disclosed |
| US-9000161-B2 | Processes for preparing JAK inhibitors and related intermediate compounds | INCYTE CORPORATION (US) | 2015-04-07 | — | — | US | disclosed |
| US-8993582-B2 | Processes for preparing JAK inhibitors and related intermediate compounds | INCYTE CORPORATION (US) | 2015-03-31 | — | — | US | disclosed |
| US-8883806-B2 | Processes for preparing JAK inhibitors and related intermediate compounds | INCYTE CORPORATION (US) | 2014-11-11 | — | — | US | disclosed |
| US-20130253190-A1 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | INCYTE CORPORATION (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130253193-A1 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | INCYTE CORPORATION (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130253191-A1 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | INCYTE CORPORATION (US) | 2013-09-26 | — | — | US | disclosed |
| US-8410265-B2 | Processes for preparing JAK inhibitors and related intermediate compounds | INCYTE CORPORATION (US) | 2013-04-02 | — | — | US | disclosed |
| EP-2398774-A2 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | Incyte Corporation (US) | 2011-12-28 | — | — | EP | disclosed |
| US-20100190981-A1 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | INCYTE CORPORATION | 2010-07-29 | — | — | US | disclosed |
| WO-2010083283-A2 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | INCYTE CORPORATION (US) | 2010-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12247030-B2 | Process for preparing compositions comprising an enantiomeric excess of a substituted pyrrolo[2,3-d]pyrimidine | DPYD, TYMS, TYMP | L3MBTL1 4553/4885SCD 2410/4885EGFR 2936/4885 |
| US-10975085-B2 | Process for preparing a composition comprising an enantiomeric excess of greater than or equal to 90% of the (R)-enantiomer of a compound of formula III | JAK1, JAK3, JAK2 | L3MBTL1 4072/4885SCD 4466/4885EGFR 434/4885 |
| US-20130253193-A1 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | JAK3, JAK1, JAK2 | L3MBTL1 4082/4885SCD 3914/4885EGFR 861/4885 |
| US-20210253584-A1 | Processes for Preparing Jak Inhibitors and Related Intermediate Compounds | JAK3, JAK1, JAK2 | L3MBTL1 4082/4885SCD 3914/4885EGFR 861/4885 |
| US-20130253190-A1 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | JAK3, JAK1, JAK2 | L3MBTL1 4082/4885SCD 3914/4885EGFR 861/4885 |
| US-10364248-B2 | Processes for preparing 4-chloro-7H-pyrrolo[2,3-d]pyrimidine | JAK1, JAK3, JAK2 | L3MBTL1 3006/4885SCD 3225/4885EGFR 1971/4885 |
| US-20100190981-A1 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | JAK3, JAK1, JAK2 | L3MBTL1 4082/4885SCD 3914/4885EGFR 861/4885 |
| US-20250340559-A1 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | JAK3, JAK1, JAK2 | L3MBTL1 4082/4885SCD 3914/4885EGFR 861/4885 |
| US-20130253191-A1 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | JAK3, JAK1, JAK2 | L3MBTL1 4082/4885SCD 3914/4885EGFR 861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.